Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed to Exhibit ColoAlert at MEDICA 2021, the World’s Largest Medical Trade Fair
November 15, 2021 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Appoints Former Roche Division President Heiner Dreismann to Strategic Advisory Board
November 11, 2021 03:01 ET | Mainz BioMed NV
Former President and CEO of Roche Molecular Systems and Member of Roche's Global Diagnostic Executive Committee BERKELEY, Calif. and MAINZ, Germany, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Mainz...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Announces Exercise of Over-Allotment Option
November 08, 2021 13:45 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Commences Trading on Nasdaq Under Ticker Symbol ‘MYNZ’
November 08, 2021 03:01 ET | Mainz BioMed NV
Flagship product ‘ColoAlert’ provides a unique, life-saving early detection test for colorectal cancerEuropean registration completed and commercial rollout underway across multiple territoriesFDA...
Mainz BioMed LOGO PANTONE@4x-100.jpg
MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market
November 05, 2021 16:23 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market
November 05, 2021 11:54 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (Nasdaq:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed N.V. Announces Pricing of Initial Public Offering
November 04, 2021 16:37 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the...